EGFR-TKI单药与传统化疗方案治疗进展期NSCLC安全性的网状meta分析

doi:10.3760/cma.j.issn.1007-1245.2024.06.003

摘要/Abstract

摘要：

目的　对一至三代表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）与传统化疗方案治疗进展期非小细胞肺癌（NSCLC）的安全性进行比较，同时采用网状meta分析方法评价三代EGFR-TKI与一、二代之间的安全性。方法　检索PubMed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国知网、万方数字化期刊全文数据库、维普数据库，检索时限均为从建库至2020年12月，搜集EGFR-TKI单药对比铂类为基础培美曲塞化疗方案的随机对照试验（RCT）。筛选文献、提取资料，并用Cochrane系统评价偏倚风险评估工具对纳入研究的RCT进行偏倚风险评估，采用RevMan 5.3软件、STATA 15.1软件进行meta分析。结果　meta分析结果显示，试验组（EGFR-TKI单药）、对照组（培美曲塞联合铂类）患者的腹泻［相对危险度（RR）=2.16，95%置信区间（CI）0.742～6.297，P>0.05］、便秘（RR=0.44，95%CI 0.187～1.039，P>0.05）发生率比较差异均无统计学意义。试验组白细胞减少发生率、中性粒细胞减少发生率、贫血发生率、血小板减少发生率、食欲不振发生率、恶心发生率均低于对照组（RR=0.21，95%CI 0.10～0.41，P<0.001；RR=0.21，95%CI 0.08～0.55，P<0.001；RR=0.26，95%CI 0.13～0.51，P<0.001；RR=0.39，95%CI 0.24～0.64，P<0.001；RR=0.39，95%CI 0.28～0.55，P<0.001；RR=0.30，95%CI 0.24～0.37，P<0.001）；试验组皮疹发生率高于对照组（RR=9.63，95%CI 6.30～14.72，P<0.001）。对一至三代EGFR-TKI的不良反应进行网状meta分析结果显示，三代EGFR-TKI奥希替尼组白细胞减少发生率要高于一、二代EGFR-TKI，贫血发生率与埃克替尼组相似，但高于吉非替尼组和阿法替尼组（均P<0.05）。结论　一至三代EGFR-TKI的血液系统、消化系统不良反应发生率均低于传统化疗方案；三代EGFR-TKI与一、二代相比，在白细胞减少及贫血发生率方面各具优势。

关键词:

非小细胞肺癌, EGFR-TKI, 不良反应, meta分析

Abstract:

Objective　In this study, we compared the safety of the first to third generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) versus conventional chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Net-work meta-analysis was used to compare the safety among different generations of EGFR-TKIs. Methods　Randomized controlled trials (RCTs) of EGFR-TKI monotherapy versus platinum-based pemetrexed chemotherapy were retrieved from PubMed, Embase, Cochrane Library, CBM, CNKI, Wanfang Database, and VIP from the establishment of the databases to December 2020. Investigators screened the literatures, extracted the information, and assessed the risk of bias for RCTs using the Cochrane Systematic Evaluation Risk of Bias Assessment Tool. The meta-analysis was performed with RevMan 5.3 software and STATA 15.1 software. Results　Seven RCTs with a total of 1 315 patients were included. Meta-analysis showed that there were no statistically significant differences in the incidence of diarrhea [relative risk (RR) = 2.16, 95% confidence interval (CI) (0.742, 6.297), P>0.05] or constipation [RR=0.44, 95%CI (0.187, 1.039), P>0.05] between the experimental group (EGFR-TKI monotherapy group) and the control group (pemetrexed combined with platinum group). The incidences of leukopenia [RR=0.21, 95%CI (0.10, 0.41), P<0.001], neutropenia [RR=0.21, 95%CI (0.08, 0.55), P<0.001], anemia [RR=0.26, 95%CI (0.13, 0.51), P<0.001], thrombocytopenia [RR=0.39, 95%CI (0.24, 0.64), P<0.001], loss of appetite [RR=0.39, 95%CI (0.28, 0.55), P<0.001], and nausea [RR=0.30, 95%CI (0.24, 0.37), P<0.001] in the experimental group were lower than those in the control group, while the incidence of rash in the experimental group was higher than that in the control group [RR=9.63, 95%CI (6.30, 14.72), P<0.001]. Network meta-analysis of the adverse events showed that the incidence of leukopenia in the third generation of EGFR-TKI osimertinib was higher than those in the first and second generations of EGFR-TKIs; the incidence of anemia in the osimertinib group was similar to that in the icotinib group, but was higher than those in the gefitinib and afatinib groups (both P<0.05). Conclusions　Compared with traditional chemotherapy regimens, the incidence of adverse reactions in the blood and digestive systems is lower in the first to third generations of EGFR-TKIs. Compared with the first and second generations, the third-generation of EGFR-TKI has advantages in reducing the incidences of leukopenia and anemia.

Key words:

NSCLC, EGFR-TKI, Adverse reactions, Meta-analysis

马静蔺婷婷董宁霞吕文文.

EGFR-TKI单药与传统化疗方案治疗进展期NSCLC安全性的网状meta分析 [J]. 国际医药卫生导报, 2024, 30(6): 897-902.

Ma Jing, Lin Tingting, Dong Ningxia, Lyu Wenwen.

Meta-analysis of the safety of EGFR-TKI monotherapy versus conventional chemotherapy in patients with advanced non-small cell lung cancer [J]. International Medicine and Health Guidance News, 2024, 30(6): 897-902.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590.
[2] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4):225-249. DOI: 10.3322/caac.20006.
[3] 陈克能,张力建,徐光炜. 化疗在进展期非小细胞肺癌治疗中的地位及其进展[J]. 国外医学(呼吸系统分册),2000,20(1):48-51. DOI:10.3760/cma.j.issn.1673- 436X.2000.01.018.
[4] 郏博,吕超,常建华,等. 非小细胞肺癌非常见突变靶向治疗研究进展[J]. 中华医学杂志,2022,102(13):969-976. DOI:10.3760/cma.j.cn112137-20211008-02215.
[5] Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation–positive non–small cell lung cancer[J]. Clin Cancer Res, 2020, 26(8): 2037-2046. DOI:10.1158/1078-0432.CCR-19-2027.
[6] Tan CS, Kumarakulasinghe NB, Huang YQ, et al, Third generation EGFR TKIs: current data and future directions[J]. Mol Cancer, 2018, 17(1): 29. DOI:10.1186/s12943- 018-0778-0.
[7] 许春伟,吕镗烽,宋勇. 机遇与挑战并存,希望与荣耀同在——不可切除局部晚期/转移性非小细胞肺癌的起始治疗策略[J]. 循证医学,2020,20(1):1-5. DOI:10.12019/j.issn.1671-5144.2020.01.001.
[8] Higgins JP, Altman DG, Gøtzsche PC, et al, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928. DOI: 10.1136/bmj.d5928.
[9] Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial[J]. Int J Cancer, 2017, 141(6): 1249-1256. DOI: 10.1002/ijc.30806.
[10] 刘丽英,王小倩,岳寒. 培美曲塞与吉非替尼治疗老年晚期肺腺癌临床观察[J]. 中国卫生标准管理,2015(16):111-113. DOI: 10.3969/j.issn.1674-9316.2015.16.086.
[11] Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol. 2017, 28(10): 2443-2450. DOI: 10.1093/annonc/mdx359.
[12] 吕杰. 不同治疗方案对EGFR突变阳性的晚期非小细胞肺癌患者的临床效果[J/CD]. 中国医学前沿杂志(电子版),2017,9(12):63-66. DOI:10.12037/YXQY.2017.12-14.
[13] 王晓燕. 培美曲塞联合顺铂与埃克替尼治疗晚期肺腺癌的临床疗效比较[J]. 海峡药学,2017,29(4):160-162. DOI:10.3969/j.issn.1006-3765.2017.04.082.
[14] Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013, 31(27): 3327-3334. DOI: 10.1200/JCO.2012.44.2806.
[15] Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer[J]. N Engl J Med, 2017, 376(7): 629-640. DOI: 10.1056/NEJMoa1612674.
[16] 周彩存,赵印敏,唐亮,等. 非小细胞肺癌组织表皮生长因子受体基因突变的临床意义[J]. 肿瘤,2005,25(5):458-461. DOI:10.3781/j.issn.1000-7431.2005.05.014.
[17] 刘正玲,李文君,陶红艳,等. EGFR突变晚期非小细胞肺癌以EGFR-TKIs为基础的治疗进展[J]. 医学综述,2021,27(22):4458-4464. DOI:10.3969/j.issn.1006-2084.2021.22.016.
[18] Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology[J]. Drug Saf, 2019, 42(2): 181-198. DOI: 10.1007/s40264-018-0772-x.
[19] 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志,2019,22(2):57-81. DOI:10.3779/j.issn.1009-3419.2019.02.01.
[20] Lee DH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures[J]. Pharmacol Ther, 2017, 174: 1-21. DOI: 10.1016/j.pharmthera.2017.02.001.
[21] 田晓江,唐学文,季欢欢,等. 基于FDA不良事件数据库对吉非替尼和厄洛替尼安全信号的检测与分析[J]. 中国新药杂志,2018,27(22):2705-2711.
[22] Remon J, Steuer CE, Ramalingam SS, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients[J]. Ann Oncol, 2018, 29 suppl_1: i20-i27. DOI: 10.1093/annonc/mdx704.
[23] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125. DOI: 10.1056/NEJMoa1713137.
[24] 薛鹏龙,李梦丽,霍礼超,等. 第一代与第二代EGFR-TKIs治疗晚期非小细胞肺癌疗效及安全性的Meta分析[J]. 现代肿瘤医学,2019,27(19):3431-3438. DOI:10.3969/j.issn.1672-4992.2019.19.017.
[25] Ding PN, Lord SJ, Gebski V, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(4): 633-643. DOI: 10.1016/j.jtho.2016.11.2236.